Fallopian Tube Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Conditions: Ovarian Clear Cell Adenocarcinoma; Platinum-Sensitive Ovarian Carcinoma; Recurrent Endometrial Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Fallopian Tube Endometrioid Adenocarcinoma; Recurrent Fallopian Tube Serous Adenocarcinoma; Recurre nt Ovarian Carcinoma; Recurrent Ovarian Clear Cell Adenocarcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Ovarian Serous Adenocarcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Primary Per itoneal Clear Cel...
Source: ClinicalTrials.gov - February 9, 2022 Category: Research Source Type: clinical trials

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
Conditions: High Grade Fallopian Tube Serous Adenocarcinoma; High Grade Ovarian Serous Adenocarcinoma; Peritoneal High Grade Serous Adenocarcinoma; Recurrent High Grade Fallopian Tube Serous Adenocarcinoma; Recurrent High Grade Ovarian Serous Adenocarcinoma; Recurrent Primary Per itoneal High Grade Serous Adenocarcinoma Interventions: Drug: Lenvatinib; Biological: Pembrolizumab Sponsor: M.D. Anderson Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 10, 2021 Category: Research Source Type: clinical trials